Clinical Trials Arena January 23, 2025
Self-described as an anti-clinical research organisation, Lindus was founded in direct response to the failure of other researchers.
Self-described anti-clinical research organisation (CRO) Lindus Health has received $55m in Series B funding to back its fully integrated, AI-driven alternative research services.
The UK-based startup launched four years ago to correct many of the shortfalls of other CROs by bringing all processes in-house and setting a single price for sponsors.
The funding round was led by new investor Balderton Capital, with support from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp. Lindus previously raised $18m in a 2023 funding round that featured participation from controversial American political figure, Peter Thiel.
Speaking with Clinical Trials Arena, Lindus Health co-founder Meri Beckwith...
Today's Sponsors
Today's Sponsor